The chairman and CEO of the Genzyme Corporation, one the nation's top five biotechnology firms, has received a phone call requesting a meeting with the cofounder and principal of a large hedge fund that now has a 2.6% stake in his firm.
Before assembly with him, the CEO is aware that he needs a strategy for coping with this "activist" investor using a track record of evacuating the CEOs.
PUBLICATION DATE: December 02, 2011 PRODUCT #: UV6529-PDF-ENG
This is just an excerpt. This case is about FINANCE & ACCOUNTING
Related Case Solutions & Analyses:
Mall of America (A)
CSFBs China Unicom Incident
Mutual Funds
MBA 510 Financial Accounting Financial Analysis Project
Note on Financial Statement Analysis
Note on Management Control Systems in Health Care
Apogee Health Care
Show Me the Money (A)
Hamilton’s Electronics Services, Inc.
Exotic Interest Rate Swaps: Snowballs in Portugal
